Robert Nelsen
Disclosed holdings of Robert Nelsen as of 2026-10-19: 13.7M shares of City Therapeutics (CTY), worth about $294M at the last close and 1 other company. In 12…
What Robert Nelsen reported holding
As of the latest filing on , Robert Nelsen reported holding 13,692,507 shares of City Therapeutics (CTY), worth about $294M at the last close of $21 (Oct 19, 2026), held through an arch venture fund xii, l.p. Holdings are also on file at Prime Medicine (PRME); together they are worth about $318M. In the last 12 months, Robert Nelsen bought $3.06M in 1 open-market purchase.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| City Therapeutics CTY | 13,692,507 | 13.7M arch venture fund xii, l.p | $21 | $294M | Oct 19, 2026 |
| Prime Medicine PRME | 6,230,300 | 6.23M arch venture fund xii, l.p | $4 | $23.9M | Aug 1, 2025 |
Is this Robert Nelsen’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Insider buying and selling since 2013
Robert Nelsen bought shares on the open market in 8 different years since 2013 across 8 companies. Sales in 1 of the 14 years since 2013.
Robert Nelsen reported 19 open-market purchases and 15 sales since 2013; purchases in 8 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | 1×1 trade | — |
| 2025 | 1×1 trade | — |
| 2024 | 3×3 trades | — |
| 2023 | 9×9 trades | — |
| 2022 | 1×1 trade | — |
| 2019 | 1×1 trade | — |
| 2018 | 2×2 trades | — |
| 2017 | — | 15×15 trades |
| 2013 | 1×1 trade | — |
Insider at 8 companies
- City Therapeutics CTY2026 · 1 purchase, 0 sales
- Prime Medicine PRME2022–2025 · 3 purchases, 0 sales
- Sana Biotechnology SANA2024 · 2 purchases, 0 sales
- Neumora Therapeutics NMRA2023 · 9 purchases, 0 sales
- Vir Biotechnology, Inc. VIR2019 · 1 purchase, 0 sales
- Twist Bioscience TWST2018 · 2 purchases, 0 sales
- Agios Pharmaceuticals AGIO2017 · 0 purchases, 15 sales
- Fate Therapeutics FATE2013 · 1 purchase, 0 sales
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. The amounts, the people and every filing are in OQRO Pro.
The companies behind these filings
- Agios Pharmaceuticals AGIO
Robert Nelsen reported 0 open-market purchases and 15 sales here, 2017.
- Market value
- $2.08B
- Last close
- $34.90
- 12 months
- −17.6%
- Against the S&P 500
- −32.9 pts
- Net margin
- -764.0%
- Revenue (last year)
- $54M
- Neumora Therapeutics NMRA
Robert Nelsen reported 9 open-market purchases and 0 sales here, 2023.
- Market value
- $88.3M
- Last close
- $0.47
- 12 months
- −72.8%
- Against the S&P 500
- −88.2 pts
- Prime Medicine PRME
Robert Nelsen reported 3 open-market purchases and 0 sales here, 2022 to 2025.
- Market value
- $695M
- Last close
- $3.83
- 12 months
- −29.7%
- Against the S&P 500
- −45.1 pts
- Net margin
- -4342.4%
- Revenue (last year)
- $4.63M
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
Trades disclosed
Latest trade
Largest trade
Companies
Every disclosed trade
Every trade this person has disclosed
Newest first, each one linked to the filing it came from.
Free account: get the written context of this page. Already a member? Sign in
What this page holds
- Every disclosed trade, newest first
- How purchases did after they were reported
- Companies and committees involved
- A link to every official filing
What OQRO is
OQRO reads the public record for US-listed companies — insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings, and federal contract awards — and puts each one in plain words next to the filing it came from. It describes what was disclosed. It does not give investment advice or tell you what to buy.
Want to see real filings before you pay? The home page shows live ones, free, with the link to each source document.
Questions about Robert Nelsen's trades
Has Robert Nelsen bought shares on the open market?
Robert Nelsen bought shares on the open market in 8 different years since 2013 across 8 companies. Sales in 1 of the 14 years since 2013.
When did Robert Nelsen last buy or sell shares?
In SEC filings since 2013: the latest open-market purchase is from 2026; the latest open-market sale is from 2017.
Which companies has Robert Nelsen traded as an insider?
8 companies: City Therapeutics (CTY, 2026), Prime Medicine (PRME, 2022–2025), Sana Biotechnology (SANA, 2024), Neumora Therapeutics (NMRA, 2023), Vir Biotechnology, Inc. (VIR, 2019) and others.